A randomized, double-blind, placebo controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

  1. Home
  2. Research
  3. Projects
  4. A randomized, double-blind, placebo controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis
Starting date
September 1, 2016
Duration (months)
60
Departments
Medicine
Managers or local contacts
Idolazzi Luca

Project participants

Luca Idolazzi
Associate Professor
Research areas involved in the project
Rheumatology  (DM)
Rheumatology  (DNBM)
Sections
Reumatologia

Activities

Research facilities

Share